Pure¹

• Highly purified HA produced by bacterial biofermentation technology
• Removes the risk of avian allergies and sensitivities
• Consistent viscolastic properties, safe for repeat injection cycles
• Fully automated manufacturing process minimizes the risk of contamination and human error

Trusted

• 35 million doses administered worldwide1† TriVisc efficacy established by equivalence to Visco-3 ®²
• Visco-3 determined to be non-inferior to Euflexxa®3 Supported by published clinical data
• TriVisc exhibited improvement in WOMAC and VAS scores compared to baseline^4,5,6

Disclosures:

• Maximum of two courses of treatment (6) units per HCP for TriVisc.
• The limits above are only for HCPs who have not requested or purchased OrthogenRx products in the past.
• For HCPs in clinics that have previously purchased an OrthogenRX product, additional documentation will be required for the possible approval of a product evaluation (PE) package (send to perequests@genvisctrivisc.com).
• Only HCPs on the approved specialty list that are licensed to prescribe and administer the products may receive the PE Units. Approved specialty list includes: Orthopedics, Rheumatology, Pain Management, Bone & Joint, Musculoskeletal, Family Medicine, Internal Medicine, Sports Medicine
• HCPs must sign the attestation that clearly and conspicuously communicates the agreement NOT to sell, bill or submit the PE units for reimbursement.

COM-TRIV-168-V1